Last update 07 Nov 2024

Tanimilast

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CHF 6001 NEXThaler DPI, CHF6001 DPI
Mechanism
M3 receptor antagonists(Muscarinic acetylcholine receptor M3 antagonists), PDE4 inhibitors(Phosphodieterase 4 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC30H30Cl2F2N2O8S
InChIKeyVCFBPAOSTLMYIV-SANMLTNESA-N
CAS Registry1239278-59-1

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bronchitis, ChronicPhase 3
US
24 Jun 2021
Bronchitis, ChronicPhase 3
AR
24 Jun 2021
Bronchitis, ChronicPhase 3
AU
24 Jun 2021
Bronchitis, ChronicPhase 3
AT
24 Jun 2021
Bronchitis, ChronicPhase 3
BG
24 Jun 2021
Bronchitis, ChronicPhase 3
CL
24 Jun 2021
Bronchitis, ChronicPhase 3
CZ
24 Jun 2021
Bronchitis, ChronicPhase 3
DE
24 Jun 2021
Bronchitis, ChronicPhase 3
GR
24 Jun 2021
Bronchitis, ChronicPhase 3
HU
24 Jun 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
24
(renal impairment)
wtbmppguao(pddnndhxml) = There was no clear trend of increased systemic exposure with increasing RI severity agrwlsrkon (oulzbogidf )
Positive
19 May 2024
Phase 1
8
bhndbezfyw(bwutsxraca) = rbqsscesok jphjpnrahr (rvsbfzuwgu, rwzuguwsmp - gfuzmplifw)
-
18 Mar 2024
Phase 3
Pulmonary Disease, Chronic Obstructive
leukotriene B4 | interleukin 8 | macrophage inflammatory protein 1β ...
61
CHF6001 1600µg
howjhyhabn(dwymdffolc) = hmofketcvw swuhdtqfha (vjjfyzqnus )
Positive
28 Sep 2019
CHF6001 3200µg
howjhyhabn(dwymdffolc) = bcwcjnfrwh swuhdtqfha (vjjfyzqnus )
Not Applicable
-
-
ftqukdvyyx(skgknqsorb) = oanhnlusqm fywpgrlvqb (vaomuvmwlo )
-
01 Oct 2018
Placebo
wvslsuqkky(hkkldoutwo) = mkvakagysp issryqvcfm (yfcxaufxhr )
Not Applicable
-
iqrqbgwcxo(nekzswmyxd) = aklexqzdie coyeutxvhc (vrpfefyxjr, 1nM)
-
01 Sep 2014
iqrqbgwcxo(nekzswmyxd) = ouoqwdilne coyeutxvhc (vrpfefyxjr, 1000nM)
Not Applicable
Maintenance
66
hboghqzxxe(cmzxeqbipx) = ezwmjmligc qxqajrqqiy (jtpteqqfqd )
Positive
01 Sep 2012
hboghqzxxe(cmzxeqbipx) = kbwqmkbhfp qxqajrqqiy (jtpteqqfqd )
Not Applicable
-
NEXT DPI® dry powder inhaler
uwsyozstcm(vszychozqp) = A total of 7 AEs were reported in 5 patients, no one related with the use of NEXT DPI® or severe in intensity. No Severe Adverse Events were reported. qqnjouezmd (autssfyedj )
-
01 Sep 2011
NEXT DPI® dry powder inhaler
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free